


PUBLICATION SPOTLIGHT

 Sentimag[®] – Sienna+[®]/Magtrace[®]

Magnetic lymph node localisation for melanoma – clinical results

Since the Sentimag[®] system was launched for lymph node localisation at the end of 2012, it has been used to treat over 100,000 cancer patients and has produced a strong base of clinical results that confirms its safety and efficacy in the nodal staging of cancer. Initial clinical data and routine use feedback for magnetic sentinel lymph node biopsy (SLNB) in melanoma suggests that magnetic lymph node localisation is feasible for an increasingly wide range of cancer indications.



Magnetic lesion localisation for melanoma – clinical results

Publications

[1] Mirzaei et al (2022): Sentinel lymph node localization and staging with a low-dose of superparamagnetic iron oxide (SPIO) enhanced MRI and magnetometer in patients with cutaneous melanoma of the extremity – The MAGMEN feasibility study. *Eur J Surg Oncol.* 2022; 48(2): 326–332. [Paper]



[2] Piñero-Madrona et al. (2020): Correlation between ferromagnetic and isotopic tracers for sentinel lymph node detection in cutaneous melanoma: IMINEM study. *J Surg Oncol.* 2020; 1-6. [Abstract]

[3] Anninga et al. (2016): Magnetic Technique for Sentinel Lymph Node Biopsy in Melanoma: The MELAMAG Trial. *Ann Surg Oncol.* 2016; 23(6):2070-8. [Abstract]



Last update September 2022

Endomag®, Sentimag® and Sienna+® are registered European Union trade marks of Endomagetics Ltd · www.endomag.com
Magtrace® is a registered trade mark of Endomagetics Ltd in the United Kingdom · www.endomag.com

Distributor EMEA: Sysmex Europe SE

Bornbarch 1, 22848 Norderstedt, Germany · Phone +49 40 52726-0 · Fax +49 40 52726-100 · oncology@sysmex-europe.com · www.sysmex-europe.com

Manufacturer: Endomagetics Ltd

330 Cambridge Science Park, Milton Road, Cambridge, CB4 0WN, United Kingdom

You will find your local Sysmex representative's address under www.sysmex-europe.com/contacts